MCE Direct Visualization of Drug Behavior in Upper-gastrointestinal Tract
Launched by CHANGHAI HOSPITAL · Mar 27, 2020
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
This pilot study was a prospective, single-centered, nonrandomized study. The investigators selected 10 subjects from patients with a recent history of upper-gastrointestinal symptoms who met the indication of taking sucralfate suspension gel, and another 10 subjects from healthy volunteers.
Procedures were performed by the NaviCam magnetic capsule guidance system. To enhance discrimination, the sucralfate gel dyed with 0.3 ml methylene blue. The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingest...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • With or without gastrointestinal complaints
- • Scheduled to undergo a capsule endoscopy for both stomach and small bowel
- • Signed the informed consents before joining this study
- Exclusion Criteria:
- • Suspected or known gastrointestinal stenosis
- • Obstruction or other known risk factors for capsule retention
- • Pregnancy or suspected pregnancy
- • Pacemakers or electromedical devices implanted
- • Any other contraindications determined by endoscopists
About Changhai Hospital
Changhai Hospital is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to excellence, the hospital integrates cutting-edge medical technologies and a multidisciplinary approach to patient care. Changhai Hospital actively collaborates with research organizations and healthcare professionals to conduct rigorous clinical trials aimed at developing new treatments and improving patient outcomes. By prioritizing patient safety and ethical standards, the hospital plays a pivotal role in contributing to the advancement of medical knowledge and the enhancement of therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Shanghai, Shanghai, China
Patients applied
Trial Officials
Zhuan Liao
Study Chair
Changhai Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials